Top-tier US medical institution Mass General Brigham Incorporated (MGB) has signed a sponsored research agreement with Chinese firm Simcere Pharmaceutical Group (HKG: 2096). The collaboration will see up to eight research groups at MGB receive funding for select projects over a two-year period, with a focus on developing new treatment options for patients with cancer, autoimmune, and central nervous system (CNS) diseases.
Expanding Research and US Presence
This agreement marks a significant step in Simcere’s expansion of its US footprint. The company already operates the Boston Innovation Center (BIC) in Cambridge, Massachusetts. In a separate announcement, Simcere revealed that its cancer-focused subsidiary, Zaiming, will establish a new unit, Simcere Zaiming Inc., also based in Massachusetts. This move is expected to bolster Simcere’s research and development capabilities in the US, particularly in the areas of cancer, autoimmune, and CNS diseases.
Implications of the Research Agreement
The research agreement with MGB underscores Simcere’s commitment to advancing medical research and expanding its global reach. By collaborating with a prestigious institution like Mass General Brigham, Simcere aims to accelerate the discovery and development of innovative therapies for serious diseases. This partnership has the potential to enhance patient outcomes and contribute to the global medical community’s understanding and treatment of cancer, autoimmune, and CNS diseases.-Fineline Info & Tech
